Literature DB >> 8376590

Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells.

M Nishinaga1, T Ozawa, K Shimada.   

Abstract

Previous studies showed that homocysteine, a thrombo-atherogenic and atherogenic agent, inhibits an endothelial thrombomodulin-protein C anticoagulant pathway. We examined whether homocysteine might affect another endothelial anticoagulant mechanism; i.e., heparin-like glycosaminoglycan-antithrombin III interactions. Incubations of porcine aortic endothelial cell cultures with homocysteine reduced the amount of antithrombin III bound to the cell surface in a dose- and time-dependent fashion. The inhibitory effect was observed at a homocysteine concentration as low as 0.1 mM, and the maximal suppression occurred at 1 mM of homocysteine after 24 h. In contrast with a marked reduction in the maximal antithrombin III binding capacity (approximately 30% of control), the radioactivity of [35S]sulfate incorporated into heparan sulfate on the cell surface was minimally (< 15%) reduced. The cells remained viable after homocysteine treatment. Although neither net negative charge nor proportion in total glycosaminoglycans of cell surface heparan sulfate was altered by homocysteine treatment, a substantial reduction in antithrombin III binding capacity of heparan sulfate isolated from homocysteine-treated endothelial cells was found using both affinity chromatography and dot blot assay techniques. The antithrombin III binding activity of endothelial cells decreased after preincubation with 1 mM homocysteine, cysteine, or 2-mercaptoethanol; no reduction in binding activity was observed after preincubation with the same concentration of methionine, alanine, or valine. This sulfhydryl effect may be caused by generation of hydrogen peroxide, as incubation of catalase, but not superoxide dismutase, with homocysteine-treated endothelial cells prevented this reduction, whereas copper augmented the inhibitory effects of the metabolite. Thus, our data suggest that the inhibited expression of anticoagulant heparan sulfate may contribute to the thrombogenic property resulting from the homocysteine-induced endothelial cell perturbation, mediated by generation of hydrogen peroxide through alteration of the redox potential.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8376590      PMCID: PMC288280          DOI: 10.1172/JCI116712

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity.

Authors:  P P Nawroth; D A Handley; C T Esmon; D M Stern
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

2.  Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator.

Authors:  G M Rodgers; W H Kane
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

Review 3.  Natural anticoagulant mechanisms.

Authors:  R D Rosenberg; J S Rosenberg
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

4.  Vessel proteoglycans and thrombogenesis.

Authors:  T N Wight
Journal:  Prog Hemost Thromb       Date:  1980

5.  Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury.

Authors:  R T Wall; J M Harlan; L A Harker; G E Striker
Journal:  Thromb Res       Date:  1980 Apr 1-15       Impact factor: 3.944

6.  The production of free radicals during the autoxidation of cysteine and their effect on isolated rat hepatocytes.

Authors:  G Saez; P J Thornalley; H A Hill; R Hems; J V Bannister
Journal:  Biochim Biophys Acta       Date:  1982-10-28

7.  Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine.

Authors:  G Starkebaum; J M Harlan
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

8.  The natural history of homocystinuria due to cystathionine beta-synthase deficiency.

Authors:  S H Mudd; F Skovby; H L Levy; K D Pettigrew; B Wilcken; R E Pyeritz; G Andria; G H Boers; I L Bromberg; R Cerone
Journal:  Am J Hum Genet       Date:  1985-01       Impact factor: 11.025

9.  Evidence that cell surface heparan sulfate is involved in the high affinity thrombin binding to cultured porcine aortic endothelial cells.

Authors:  K Shimada; T Ozawa
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

10.  Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan.

Authors:  J A Marcum; D H Atha; L M Fritze; P Nawroth; D Stern; R D Rosenberg
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157

View more
  24 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy?

Authors:  Zeki Yesilova; Salih Pay; Cagatay Oktenli; Ugur Musabak; Kenan Saglam; S Yavuz Sanisoglu; Kemal Dagalp; M Kemal Erbil; Ismail H Kocar
Journal:  Rheumatol Int       Date:  2004-04-01       Impact factor: 2.631

Review 3.  Synergy of homocysteine, microRNA, and epigenetics: a novel therapeutic approach for stroke.

Authors:  Anuradha Kalani; Pradeep K Kamat; Suresh C Tyagi; Neetu Tyagi
Journal:  Mol Neurobiol       Date:  2013-02-22       Impact factor: 5.590

4.  The role of methylenetetrahydrofolate reductase C677T polymorphism on the peripheral blood natural killer cell proportion in women with unexplained recurrent miscarriages.

Authors:  Chan Woo Park; Ae Ra Han; Joanne Kwak-Kim; So Yeon Park; Jung Yeol Han; Mi Kyoung Koong; In Ok Song; Kwang Moon Yang
Journal:  Clin Exp Reprod Med       Date:  2011-09-30

5.  Interaction of CA repeat polymorphism of the endothelial nitric oxide synthase and hyperhomocysteinemia in acute coronary syndromes: evidence of gender-specific differences.

Authors:  Michael Laule; Christian Meisel; Ines Prauka; Ingolf Cascorbi; Uwe Malzahn; Stephan B Felix; Gert Baumann; Ivar Roots; Karl Stangl; Verena Stangl
Journal:  J Mol Med (Berl)       Date:  2003-04-02       Impact factor: 4.599

6.  Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate.

Authors:  S L Tokgözoğlu; M Alikaşifoğlu; E Atalar; K Aytemir; N Ozer; K Ovünç; O Usal; S Kes; E Tunçbilek
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

Review 7.  Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease.

Authors:  Alla V Glushchenko; Donald W Jacobsen
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

Review 8.  Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk.

Authors:  Elisabetta Trabetti
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

9.  Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behçet's disease.

Authors:  Abdullah Canataroglu; Kahraman Tanriverdi; Tamer Inal; Gulsah Seydaoglu; Didem Arslan; Suleyman Ozbek; Fikri Baslamisli
Journal:  Rheumatol Int       Date:  2003-03-14       Impact factor: 2.631

Review 10.  The association of homocysteine and coronary artery disease.

Authors:  Gregory M Gauthier; Jon G Keevil; Patrick E McBride
Journal:  Clin Cardiol       Date:  2003-12       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.